-Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy

Featured Article:

Lindsay B. Harrison, M.D., Beverley Adams-Huet, M.S., Philip Raskin, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S.

Diabetes Care Volume 35: 1406-1412

July, 2012

Study Objectives

 

Harrison L et al. Diabetes Care 2012;35:1406-1412

• To assess -cell function preservation after 3.5 years of intensive therapy with:

Insulin plus metformin (INS group)

vs.

Triple oral therapy (TOT group) with metformin, glyburide, and pioglitazone

 

Study Design & Methods

• Randomized trial of 58 patients with treatment-naïve newly diagnosed type 2 diabetes

• All patients treated with insulin and metformin for a 3-month lead-in period

• Followed by random assignment to the INS or TOT group

• -Cell function assessed using a mixed-meal challenge test at randomization and 6, 12, 18, 30, and 42 months

• Analyses were intention to treat and performed with repeated-measures models

Harrison L et al. Diabetes Care 2012;35:1406-1412

Harrison L et al. Diabetes Care 2012;35:1406-1412

Harrison L et al. Diabetes Care 2012;35:1406-1412

Harrison L et al. Diabetes Care 2012;35:1406-1412

Harrison L et al. Diabetes Care 2012;35:1406-1412

Conclusions

• -Cell function can be preserved for at least 3.5 years with early and intensive therapy for type 2 diabetes with either insulin plus metformin or triple oral therapy after an initial 3-month insulin-based treatment period

Harrison L et al. Diabetes Care 2012;35:1406-1412